Abstract:
Leishmaniasis are common parasitic diseases in the Mediterranean basin. In Algeria, they are one of the notifiable diseases. The cutaneous form of this parasite is the form available in Ghardaïa, as in other regions of southern Algeria. Glucantime® or N-methylglucamine antimonate is the most widely prescribed molecule for treating leishmaniasis in our country. This molecule can be sometimes responsible for serious adverse effects. The present work aims to establish a retrospective statistical survey during 2013-2021 and to verify the impact of Glucantime® treatment on the renal and hepatic balances of patients treated during the year 2022. Microscopy was used as the diagnostic technique, and where 248 patients with cutaneous leishmaniasis (CL) were collected at the EPSP laboratory in the commune of Berriane. The age group most affected was (20-45) years, with a male predominance in 64.52% of cases. According to our retrospective study spanning the last 10 years, the maximum number of cases was reported in 2020, with 39 cases. Most positive cases were recorded during the autumn-winter period in the study year 2022. According to the results of biochemical tests (liver and kidney function tests) obtained, there were no adverse reactions to Glucantime® reported in our series of patients treated with this medicament.
